GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (OTCPK:CSBTF) » Definitions » 3-Year EPS without NRI Growth Rate

CSBTF (Kuros Biosciences) 3-Year EPS without NRI Growth Rate : 24.20% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Kuros Biosciences 3-Year EPS without NRI Growth Rate?

Kuros Biosciences's EPS without NRI for the six months ended in Dec. 2024 was $-0.10.

During the past 3 years, the average EPS without NRI Growth Rate was 24.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 47.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Kuros Biosciences was 82.90% per year. The lowest was -70.20% per year. And the median was 32.15% per year.


Competitive Comparison of Kuros Biosciences's 3-Year EPS without NRI Growth Rate

For the Medical Devices subindustry, Kuros Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences's 3-Year EPS without NRI Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's 3-Year EPS without NRI Growth Rate falls into.


;
;

Kuros Biosciences 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Kuros Biosciences  (OTCPK:CSBTF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Kuros Biosciences 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.